Concord Biotech Limited
₹1,245.30+₹15.40 (+1.3%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹14,122 Cr
- P/E
- 43.9x
- EV / EBITDA
- 30.0x
- Revenue
- ₹1,200 Cr
- Net margin
- 30.0%
- ROCE
- 28.1%
Price chart
Technical chartScreen technicals →-14.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -9.3%
- 3M
- -6.6%
- 6M
- +9.2%
- 1Y
- -14.3%
- 5Y
- +32.2%
52-week range
Day change +₹15.40 (+1.3%) from ₹1,230 to ₹1,245 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in CONCORDBIO, bought on each weekday since 2023.
AI Summary
Indian StockStrengths1
- Healthy return on equity of 20.0%
Concerns0
Rule-based from financial data. Not advice.
About the company
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas.
Read moreShow less
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
- Sector
- Technology
- Shares outstanding
- 10.4 Cr shares
- ISIN
- INE338H01029
- BSE code
- 543960
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹14,122 Cr
- P/E
- 43.9x
- P/B
- 7.8x
- EV / EBITDA
- 30.0x
- EV / Sales
- 13.8x
- P/S
- 13.9x
- Earnings yield
- 2.3%
- 52-week high
- ₹1,585.10
- 52-week low
- ₹1,014.05
Profitability
- Operating margin
- 42.5%
- Net margin
- 30.0%
- EBITDA margin
- 45.8%
- ROE
- 20.0%
- ROCE
- 28.1%
- ROA
- 18.0%
- Dividend payout
- 30.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 8.3%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,200 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 18.0%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.7%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹466 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 23.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 22.3%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.5%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹265 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹14.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.1%
Solvency and efficiency
- Current ratio
- 5.56
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- Debt / EBITDA
- 0.02
- Interest coverage
- 144.00
- Financial leverage
- 1.11
- CFO / Net profit
- 0.87
- Cash / Market cap
- 4.7%
- Cash per share
- ₹63.95
- Asset turnover
- 0.60
- Fixed asset turnover
- 1.77
- Capital intensity
- 0.57
- Debtor days
- 125 days
- Inventory turnover
- 1.10
- Cash conversion cycle
- 306 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹31 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹693 Cr |
| Sales | Operating profit | ₹507 Cr |
| Operating profit | Interest | ₹1 Cr |
| Operating profit | Depreciation | ₹54 Cr |
| Operating profit | Profit before tax | ₹452 Cr |
| Other income | Profit before tax | ₹44 Cr |
| Profit before tax | Tax and other | ₹123 Cr |
| Profit before tax | Net profit | ₹373 Cr |
Revenue and net profit
Revenue grew 18.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹617 Cr | ₹235 Cr |
| FY2022 | ₹713 Cr | ₹179 Cr |
| FY2023 | ₹853 Cr | ₹238 Cr |
| FY2024 | ₹1,017 Cr | ₹305 Cr |
| FY2025 | ₹1,200 Cr | ₹373 Cr |
Cash flows
FY2025: ₹245 Cr from operations, ₹85.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹167 Cr | -₹28 Cr |
| FY2022 | ₹207 Cr | ₹95 Cr |
| FY2023 | ₹246 Cr | ₹88 Cr |
| FY2024 | ₹265 Cr | ₹110 Cr |
| FY2025 | ₹245 Cr | ₹85 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,200 Cr+18.0%1Y
- Net profit
- ₹373 Cr+22.3%1Y
- Cash from operations
- ₹245 Cr
- Free cash flow
- ₹85 Cr-22.7%1Y
- Revenue CAGR, 5Y
- 14.7%
- EBITDA CAGR, 5Y
- 14.6%
- Net profit CAGR, 5Y
- 12.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,200 Cr | ₹507 Cr | — | ₹373 Cr | ₹245 Cr | ₹85 Cr | 20.6% | +18.0% | +22.3% |
Monthly returns
Month-by-month returns of CONCORDBIO across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,034 Cr |
| Equity capital | ₹10 Cr |
| Reserves | ₹1,802 Cr |
| Borrowings | ₹3 Cr |
| Other liabilities | ₹219 Cr |
| Assets | ₹2,034 Cr |
| Fixed assets | ₹795 Cr |
| Capital work in progress | ₹51 Cr |
| Investments | ₹335 Cr |
| Other assets | ₹854 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
CONCORDBIO trades at 43.9x earnings against a peer median of 52.1x (a 16% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Concord Biotech LimitedCONCORDBIOthis companyP/E ↓ discount | ₹14,122 Cr | 43.9x | 7.8x | 20.0% | 30.0x |
| Aditya Infotech LimitedCPPLUS | ₹16,700 Cr | 94.8x | 12.1x | 33.6% | 69.8x |
| Zensar Technologies Ltd.ZENSARTECH | ₹16,218 Cr | 26.0x | 5.1x | 17.8% | 23.0x |
| CarTrade Tech LimitedCARTRADE | ₹13,418 Cr | 138.0x | 6.0x | 2.0% | 216.1x |
| Cyient LimitedCYIENT | ₹13,048 Cr | 29.8x | 3.4x | 16.9% | 16.6x |
| INTELLECT DESIGN ARENA LIMITEDINTELLECT | ₹12,976 Cr | 52.1x | 6.6x | 9.4% | 35.5x |
| Indegene LimitedINDGN | ₹12,308 Cr | 58.9x | 6.3x | 14.5% | 56.1x |
| BIRLASOFT LIMITEDBSOFT | ₹11,840 Cr | 43.0x | 7.1x | 20.4% | 24.6x |
| Zen Technologies Ltd.ZENTEC | ₹11,156 Cr | 53.9x | 6.3x | 28.5% | 57.2x |
| Peer median | — | 52.1x | 7.8x | 14.5% | 34.2x |
Year-to-date ROI
CONCORDBIO since 1 January, against earlier years.
Historical volatility
CONCORDBIO's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 53.0% |
| FY2022 | 38.0% |
| FY2023 | 40.0% |
| FY2024 | 42.0% |
| FY2025 | 42.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,200 Cr |
| Costs | |
| Interest | ₹1 Cr |
| Expenses | ₹693 Cr |
| Operating profitOperating Profit | ₹507 Cr |
| Other income and charges | |
| Profit before tax | ₹496 Cr |
| Tax | |
| Net profitNet Profit | ₹373 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,034 Cr |
| Equity capitalEquity Capital | ₹10 Cr |
| Reserves | ₹1,802 Cr |
| Borrowings | ₹3 Cr |
| Other liabilitiesOther Liabilities | ₹219 Cr |
| AssetsTotal Assets | ₹2,034 Cr |
| Fixed assetsFixed Assets | ₹795 Cr |
| Capital work in progressCWIP | ₹51 Cr |
| Investments | ₹335 Cr |
| Other assetsOther Assets | ₹854 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹245 Cr |
| Investing cash flowCash from Investing Activity | -₹160 Cr |
| Financing cash flowCash from Financing Activity | -₹99 Cr |
| Change in cashNet Cash Flow | -₹14 Cr |
Learn while you research
Academy chapters picked for Concord Biotech Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 43.9, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Growth InvestingTech & communications often trade on growth, learn the framework.7 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read